Literature DB >> 22851268

Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial and Re: CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.

Paul D P Pharoah, Jean Abraham, Carlos Caldas.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22851268     DOI： 10.1093/jnci/djs312

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  15 in total

1.  Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters.

Authors:  Hiltrud Brauch; Werner Schroth; Matthew P Goetz; Thomas E Mürdter; Stefan Winter; James N Ingle; Matthias Schwab; Michel Eichelbaum
Journal:  J Clin Oncol       Date:  2012-10-22       Impact factor: 44.544

2.  Breast cancer recurrence in relation to antidepressant use.

Authors:  Jessica Chubak; Erin J A Bowles; Onchee Yu; Diana S M Buist; Monica Fujii; Denise M Boudreau
Journal:  Cancer Causes Control       Date:  2015-10-30       Impact factor: 2.506

3.  Re: Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA.

Authors:  Matthew P Goetz; Hiltrud Brauch; Mark J Ratain; Nancy J Cox; Yusuke Nakamura; Richard Weinshilboum; James N Ingle
Journal:  J Natl Cancer Inst       Date:  2014-04-03       Impact factor: 13.506

Review 4.  'Toxgnostics': an unmet need in cancer medicine.

Authors:  David Church; Rachel Kerr; Enric Domingo; Dan Rosmarin; Claire Palles; Kevin Maskell; Ian Tomlinson; David Kerr
Journal:  Nat Rev Cancer       Date:  2014-05-15       Impact factor: 60.716

Review 5.  Cytochrome P-450 2D6 (CYP2D6) Genotype and Breast Cancer Recurrence in Tamoxifen-Treated Patients: Evaluating the Importance of Loss of Heterozygosity.

Authors:  Thomas P Ahern; Daniel L Hertz; Per Damkier; Bent Ejlertsen; Stephen J Hamilton-Dutoit; James M Rae; Meredith M Regan; Alastair M Thompson; Timothy L Lash; Deirdre P Cronin-Fenton
Journal:  Am J Epidemiol       Date:  2016-12-17       Impact factor: 4.897

6.  Trends in co-prescribing of antidepressants and tamoxifen among women with breast cancer, 2004-2010.

Authors:  Stacie B Dusetzina; G Caleb Alexander; Rachel A Freedman; Haiden A Huskamp; Nancy L Keating
Journal:  Breast Cancer Res Treat       Date:  2012-11-13       Impact factor: 4.872

7.  Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA.

Authors:  James M Rae; Meredith M Regan; Jacklyn N Thibert; Christina Gersch; Dafydd Thomas; Brian Leyland-Jones; Giuseppe Viale; Lajos Pusztai; Daniel F Hayes; Todd Skaar; Catherine Van Poznak
Journal:  J Natl Cancer Inst       Date:  2013-08-19       Impact factor: 13.506

Review 8.  Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy.

Authors:  Deirdre P Cronin-Fenton; Per Damkier; Timothy L Lash
Journal:  Future Oncol       Date:  2014-01       Impact factor: 3.404

9.  Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies.

Authors:  Matthew P Goetz; James X Sun; Vera J Suman; Grace O Silva; Charles M Perou; Yusuke Nakamura; Nancy J Cox; Philip J Stephens; Vincent A Miller; Jeffrey S Ross; David Chen; Stephanie L Safgren; Mary J Kuffel; Matthew M Ames; Krishna R Kalari; Henry L Gomez; Ana M Gonzalez-Angulo; Octavio Burgues; Hiltrud B Brauch; James N Ingle; Mark J Ratain; Roman Yelensky
Journal:  J Natl Cancer Inst       Date:  2014-12-08       Impact factor: 13.506

Review 10.  Pharmacogenomics of breast cancer therapy: an update.

Authors:  Kelly Westbrook; Vered Stearns
Journal:  Pharmacol Ther       Date:  2013-03-13       Impact factor: 12.310
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.